Pure Global

MP Diagnostics ASSURE H. pylori Rapid Test (Qualitative Antibody Test for H. pylori in serum, plasma, and whole blood from humans) - Vietnam Registration 240000525/PCBB-HCM

Access comprehensive regulatory information for MP Diagnostics ASSURE H. pylori Rapid Test (Qualitative Antibody Test for H. pylori in serum, plasma, and whole blood from humans) in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại B medical device is registered under number 240000525/PCBB-HCM and manufactured by MP BIOMEDICALS ASIA PACIFIC PTE. LTD. The authorized representative in Vietnam is CÔNG TY TNHH THIẾT BỊ Y TẾ HOÀNG LÊ.

This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.

Free Database
Powered by Pure Global AI
300,000+ Devices
240000525/PCBB-HCM
Registration Details
Vietnam MOH Registration: 240000525/PCBB-HCM
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

Device Details

MP Diagnostics ASSURE H. pylori Rapid Test (Qualitative Antibody Test for H. pylori in serum, plasma, and whole blood from humans)
VN: MP Diagnostics ASSURE H. pylori Rapid Test ( Xét nghiệm định tính kháng thể kháng vi khuẩn H.pylori trong huyết thanh, huyết tương, máu toàn phần người)
MP Diagnostics ASSURE H. pylori Rapid Test
Risk Class TTBYT Loại B

Registration Details

240000525/PCBB-HCM

000.00.19.H29-240304-0017

Theo theo phụ lục

Theo phụ lục

Company Information

Theo theo phụ lục

MP BIOMEDICALS ASIA PACIFIC PTE. LTD

Technical Details

MP Diagnostics ASSURE H.pylori Rapid Test is an immunological test device that quickly detects the presence of Helicobacter pylori-specific IgG antibodies in serum, plasma, or whole blood. It is intended as a clinical diagnostic test to diagnose H. pylori infection in patients with gastrointestinal disorders. The presence of antibodies against the recombinant infection marker (CIM) is an indicator of active infection

Dates and Status

Mar 07, 2024